🎉 M&A multiples are live!
Check it out!

Trevi Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Trevi Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Trevi Therapeutics Overview

About Trevi Therapeutics

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.


Founded

2011

HQ

United States of America
Employees

26

Financials

LTM Revenue n/a

LTM EBITDA -$55.0M

EV

$469M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Trevi Therapeutics Financials

Trevi Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$55.0M.

In the most recent fiscal year, Trevi Therapeutics achieved revenue of n/a and an EBITDA of -$47.8M.

Trevi Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Trevi Therapeutics valuation multiples based on analyst estimates

Trevi Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$28.6M -$47.8M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$29.2M -$29.1M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Trevi Therapeutics Stock Performance

As of April 15, 2025, Trevi Therapeutics's stock price is $6.

Trevi Therapeutics has current market cap of $575M, and EV of $469M.

See Trevi Therapeutics trading valuation data

Trevi Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$469M $575M XXX XXX XXX XXX $-0.49

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Trevi Therapeutics Valuation Multiples

As of April 15, 2025, Trevi Therapeutics has market cap of $575M and EV of $469M.

Trevi Therapeutics's trades at n/a LTM EV/Revenue multiple, and -8.5x LTM EBITDA.

Analysts estimate Trevi Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Trevi Therapeutics and 10K+ public comps

Trevi Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $469M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -9.8x XXX XXX XXX
P/E -12.0x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -12.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Trevi Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Trevi Therapeutics Valuation Multiples

Trevi Therapeutics's NTM/LTM revenue growth is n/a

Trevi Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $2.0M for the same period.

Over next 12 months, Trevi Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Trevi Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Trevi Therapeutics and other 10K+ public comps

Trevi Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 67% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $2.0M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Trevi Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Trevi Therapeutics M&A and Investment Activity

Trevi Therapeutics acquired  XXX companies to date.

Last acquisition by Trevi Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Trevi Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Trevi Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Trevi Therapeutics

When was Trevi Therapeutics founded? Trevi Therapeutics was founded in 2011.
Where is Trevi Therapeutics headquartered? Trevi Therapeutics is headquartered in United States of America.
How many employees does Trevi Therapeutics have? As of today, Trevi Therapeutics has 26 employees.
Who is the CEO of Trevi Therapeutics? Trevi Therapeutics's CEO is Ms. Jennifer L. Good.
Is Trevi Therapeutics publicy listed? Yes, Trevi Therapeutics is a public company listed on NAS.
What is the stock symbol of Trevi Therapeutics? Trevi Therapeutics trades under TRVI ticker.
When did Trevi Therapeutics go public? Trevi Therapeutics went public in 2019.
Who are competitors of Trevi Therapeutics? Similar companies to Trevi Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Trevi Therapeutics? Trevi Therapeutics's current market cap is $575M
What is the current EBITDA of Trevi Therapeutics? Trevi Therapeutics's last 12-month EBITDA is -$55.0M.
What is the current EV/EBITDA multiple of Trevi Therapeutics? Current EBITDA multiple of Trevi Therapeutics is -8.5x.
Is Trevi Therapeutics profitable? Yes, Trevi Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.